Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical trial data translates to real-world practice. Utilizing recent data to guide first-line maintenance therapy, particularly for ovarian cancer (OC), can be especially informative, helping to prolong the response of front-line therapy and delay the need for additional therapies. Members of the multidisciplinary team tasked with care for patients with OC need to know about potential therapy options and determine the value of each for those patients recently diagnosed or living with recurrent OC.
In the fifth activity of this CME Outfitters podcast series on gynecologic cancers, expert faculty will present and discuss the very latest research that guides the use of first-line maintenance therapy for the treatment of OC.
At the conclusion of this activity, learners will be able to better:
Supported by independent educational grants from AstraZeneca Pharmaceuticals and Merck & Co., Inc., Rahway, NJ, USA.
Gynecologic oncologists, medical oncologists, gynecologists, physician associates (PAs), nurses, nurse practitioners (NPs), and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-093-H01-P).
This activity is designated for 0.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 12/31/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Penson reports the following financial relationships:
Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics
Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche
Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD, and CME Outfitters
Dr. Herzog reports the following financial relationships:
Advisory Board/Consulting: Aadi Bioscience; AbbVie Inc. (ImmunoGen, Inc.); AstraZeneca; Caris Life Sciences; Clovis Oncology, Inc.; Corcept Therapeutics; Eisai Inc.; Epsilogen; Genentech, Inc.; GSK; Johnson & Johnson; Merck & Co., Inc.; Mersana Therapeutics; Novocure; and Pfizer Inc. (Seagen Inc.)
Other financial or material support: President, The GOG Foundation President Inc.
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
PD-111-123124-90